Literature DB >> 10993656

Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines.

J R Kroep1, G Giaccone, C Tolis, D A Voorn, W J Loves, C J Groeningen, H M Pinedo, G J Peters.   

Abstract

Gemcitabine and paclitaxel are active agents in the treatment of non-small-cell lung cancer (NSCLC). To optimize treatment drug combinations, simultaneously and 4 and 24 h intervals, were studied using DNA flow cytometry and multiple drug effect analysis in the NSCLC cell lines H460, H322 and Lewis Lung. All combinations resulted in comparable cytotoxicity, varying from additivity to antagonism (combination index: 1.0-2.6). Gemcitabine caused a S (48%) and G1 (64%) arrest at IC-50 and 10 x IC-50 concentrations, respectively. Paclitaxel induced G2/M arrest (70%) which was maximal within 24 h at 10 x IC-50. Simultaneous treatment increased S-phase arrest, while at the 24 h interval after 72 h the first drug seemed to dominate the effect. Apoptosis was more pronounced when paclitaxel preceded gemcitabine (20% for both intervals) as compared to the reverse sequence (8%, P = 0.173 for the 4 h and 12%, P = 0.051 for the 24 h time interval). In H460 cells, paclitaxel increased 2-fold the accumulation of dFdCTP, the active metabolite of gemcitabine, in contrast to H322 cells. Paclitaxel did not affect deoxycytidine kinase levels, but ribonucleotide levels increased possibly explaining the increase in dFdCTP. Paclitaxel did not affect gemcitabine incorporation into DNA, but seemed to increase incorporation into RNA. Gemcitabine almost completely inhibited DNA synthesis in both cell lines (70-89%), while paclitaxel had a minor effect and did not increase that of gemcitabine. In conclusion, various gemcitabine-paclitaxel combinations did not show sequence dependent cytotoxic effects; all combinations were not more than additive. However, since paclitaxel increased dFdCTP accumulation, gemcitabine incorporation into RNA and the apoptotic index, the administration of paclitaxel prior to gemcitabine might be favourable as compared to reversed sequences. Copyright 2000 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10993656      PMCID: PMC2363564          DOI: 10.1054/bjoc.2000.1399

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines.

Authors:  C Theodossiou; J A Cook; J Fisher; D Teague; J E Liebmann; A Russo; J B Mitchell
Journal:  Int J Oncol       Date:  1998-04       Impact factor: 5.650

Review 2.  A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer.

Authors:  S V Rajkumar; A A Adjei
Journal:  Cancer Treat Rev       Date:  1998-02       Impact factor: 12.111

3.  Evaluation of in vivo induction of apoptosis in patients with acute leukemia treated on a phase I study of paclitaxel.

Authors:  K Seiter; E J Feldman; F Traganos; X Li; H D Halicka; Z Darzynkiewicz; C A Lederman; M B Romero; T Ahmed
Journal:  Leukemia       Date:  1995-11       Impact factor: 11.528

4.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

5.  Gemcitabine: Future Prospects of Single-Agent and Combination Studies.

Authors: 
Journal:  Oncologist       Date:  1997

6.  Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.

Authors:  C J van Moorsel; A M Bergman; G Veerman; D A Voorn; V W Ruiz van Haperen; J R Kroep; H M Pinedo; G J Peters
Journal:  Biochim Biophys Acta       Date:  2000-03-06

7.  Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues.

Authors:  T Spasokoukotskaja; E S Arnér; O Brosjö; P Gunvén; G Juliusson; J Liliemark; S Eriksson
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

8.  Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells.

Authors:  J E Liebmann; J Fisher; D Teague; J A Cook
Journal:  Oncol Res       Date:  1994       Impact factor: 5.574

9.  Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro.

Authors:  S M Hahn; J E Liebmann; J Cook; J Fisher; B Goldspiel; D Venzon; J B Mitchell; D Kaufman
Journal:  Cancer       Date:  1993-11-01       Impact factor: 6.860

10.  Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.

Authors:  C J van Moorsel; H M Pinedo; G Veerman; A M Bergman; C M Kuiper; J B Vermorken; W J van der Vijgh; G J Peters
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

View more
  17 in total

1.  Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells.

Authors:  Emilie A G Molins; William J Jusko
Journal:  AAPS J       Date:  2018-06-27       Impact factor: 4.009

2.  Prediction of multidimensional drug dose responses based on measurements of drug pairs.

Authors:  Anat Zimmer; Itay Katzir; Erez Dekel; Avraham E Mayo; Uri Alon
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-25       Impact factor: 11.205

3.  Significant impact of divalent metal ions on the fidelity, sugar selectivity, and drug incorporation efficiency of human PrimPol.

Authors:  E John Tokarsky; Petra C Wallenmeyer; Kenneth K Phi; Zucai Suo
Journal:  DNA Repair (Amst)       Date:  2016-11-25

4.  Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates.

Authors:  Rui Zhang; Jiyuan Yang; Monika Sima; Yan Zhou; Jindřich Kopeček
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

5.  Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial.

Authors:  Keun Seok Lee; Jungsil Ro; Eun Sook Lee; Han Sung Kang; Seok Won Kim; Byung-Ho Nam; Youngmee Kwon; Eun-A Kim; Kyung Hwan Shin
Journal:  Invest New Drugs       Date:  2009-02-20       Impact factor: 3.850

6.  Mixed Liposome Approach for Ratiometric and Sequential Delivery of Paclitaxel and Gemcitabine.

Authors:  Yuanfen Liu; Hassan Tamam; Yoon Yeo
Journal:  AAPS PharmSciTech       Date:  2017-10-02       Impact factor: 3.246

7.  nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

Authors:  Kristopher K Frese; Albrecht Neesse; Natalie Cook; Tashinga E Bapiro; Martijn P Lolkema; Duncan I Jodrell; David A Tuveson
Journal:  Cancer Discov       Date:  2012-02-28       Impact factor: 39.397

8.  A NAG-Guided Nano-Delivery System for Redox- and pH-Triggered Intracellularly Sequential Drug Release in Cancer Cells.

Authors:  Yan Liang; Jing Zhang; Baocheng Tian; Zimei Wu; Darren Svirskis; Jingtian Han
Journal:  Int J Nanomedicine       Date:  2020-02-05

9.  Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.

Authors:  Stacy S Shord; Shitalben R Patel
Journal:  J Exp Clin Cancer Res       Date:  2009-06-06

10.  Gemcitabine and taxanes in metastatic breast cancer: a systematic review.

Authors:  Vinay Gudena; Alberto J Montero; Stefan Glück
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.